k8com官网

Be the most trusted biotech company

2022-10-25

Henlius Anti-PD-1 mAb Serplulimab Combined with Chemotherapy and Concurrent Radiotherapy MRCT Phase 3 Study on First-Line LS-SCLC Patients Received Clinical Trial Approved in Australia
2022-10-17

The IND Application of Henlius’ Novel Anti-GARP mAb HLX60 Approved by NMPA
2022-09-30

Henlius completed the phase 1 clinical trial of HLX22 for the treatment of HER2 overexpressing advanced solid tumours
2022-09-29

Henlius Received IND Approval from US FDA for HLX07 in CSCC patients
2022-09-28

ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world
2022-09-08

Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HANBEITAI in Patients with Advanced Hepatocellular Carcinoma Published in Liver Cancer
2022-08-15

First Subject Dosed of the Phase 1 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Advanced/Metastatic Solid Tumours Patients
2022-07-29

Mars landing H - Boarding Call for Innovation
2022-07-25

Henlius HANQUYOU Received TGA Approval in Australia

1
2
3
4
5
...
7